{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T22:16:39Z","timestamp":1778969799893,"version":"3.51.4"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T00:00:00Z","timestamp":1583452800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-16-1-0219"],"award-info":[{"award-number":["W81XWH-16-1-0219"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RSG-12-199-01-TBG"],"award-info":[{"award-number":["RSG-12-199-01-TBG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NF Northeast; Manth Family"},{"DOI":"10.13039\/100010240","name":"Nancy Sayles Day Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010240","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010572","name":"Lauer Tinnitus Research Center, Massachusetts Eye and Ear","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010572","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000055","name":"U.S. Department of Health & Human Services | NIH | National Institute on Deafness and Other Communication Disorders","doi-asserted-by":"publisher","award":["R01DC015824"],"award-info":[{"award-number":["R01DC015824"]}],"id":[{"id":"10.13039\/100000055","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Neurofibromatosis type 2 (NF2) is an inherited disorder characterized by bilateral vestibular schwannomas (VS) that arise from neoplastic Schwann cells (SCs). NF2-associated VSs are often accompanied by meningioma (MN), and the majority of NF2 patients show loss of the <jats:italic>NF2<\/jats:italic> tumor suppressor. mTORC1 and mTORC2-specific serum\/glucocorticoid-regulated kinase 1 (SGK1) are constitutively activated in MN with loss of <jats:italic>NF2<\/jats:italic>. In a recent high-throughput kinome screen in <jats:italic>NF2<\/jats:italic>-null human arachnoidal and meningioma cells, we showed activation of EPH RTKs, c-KIT, and SFK members independent of mTORC1\/2 activation. Subsequently, we demonstrated <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic> efficacy of combination therapy with the dual mTORC1\/2 inhibitor AZD2014 and the multi-kinase inhibitor dasatinib. For these reasons, we investigated activated mTORC1\/2 and EPH receptor-mediated signaling in sporadic and NF2-associated VS. Using primary human VS cells and a mouse allograft model of schwannoma, we evaluated the dual mTORC1\/2 inhibitor AZD2014 and the tyrosine kinase inhibitor dasatinib as monotherapies and in combination. Escalating dose-response experiments on primary VS cells grown from 15 human tumors show that combination therapy with AZD2014 and dasatinib is more effective at reducing metabolic activity than either drug alone and exhibits a therapeutic effect at a physiologically reasonable concentration (~0.1\u2009\u00b5M). <jats:italic>In vivo<\/jats:italic>, while AZD2014 and dasatinib each inhibit tumor growth alone, the effect of combination therapy exceeds that of either drug. Co-targeting the mTOR and EPH receptor pathways with these or similar compounds may constitute a novel therapeutic strategy for VS, a condition for which there is no FDA-approved pharmacotherapy.<\/jats:p>","DOI":"10.1038\/s41598-020-60156-6","type":"journal-article","created":{"date-parts":[[2020,3,6]],"date-time":"2020-03-06T11:03:15Z","timestamp":1583492595000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma"],"prefix":"10.1038","volume":"10","author":[{"given":"Jessica E.","family":"Sagers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta L.","family":"Beauchamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasa","family":"Vasilijic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Limeng","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"DeSouza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Seist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjianlong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0525-183X","authenticated-orcid":false,"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijaya","family":"Ramesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantina M.","family":"Stankovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,6]]},"reference":[{"key":"60156_CR1","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1097\/MAO.0000000000000239","volume":"35","author":"SR Plotkin","year":"2014","unstructured":"Plotkin, S. R., Merker, V. L., Muzikansky, A., Barker, F. G. II. & Slattery, W. III. Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. Otol. Neurotol. 35, e50\u201356 (2014).","journal-title":"Otol. Neurotol."},{"key":"60156_CR2","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1055\/s-0030-1253576","volume":"20","author":"AK Demetriades","year":"2010","unstructured":"Demetriades, A. K. et al. Malignant transformation of acoustic neuroma\/vestibular schwannoma 10 years after gamma knife stereotactic radiosurgery. Skull Base. 20, 381\u2013387 (2010).","journal-title":"Skull Base."},{"key":"60156_CR3","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/S0140-6736(02)09521-1","volume":"360","author":"M Shin","year":"2002","unstructured":"Shin, M., Ueki, K., Kurita, H. & Kirino, T. Malignant transformation of a vestibular schwannoma after gamma knife radiosurgery. Lancet. 360, 309\u2013310 (2002).","journal-title":"Lancet."},{"issue":"593","key":"60156_CR4","first-page":"e591","volume":"79","author":"V Yanamadala","year":"2013","unstructured":"Yanamadala, V. et al. Malignant transformation of a vestibular schwannoma after gamma knife radiosurgery. World Neurosurg. 79(593), e591\u2013598 (2013).","journal-title":"World Neurosurg."},{"key":"60156_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2014.12.007","volume":"166","author":"S Dilwali","year":"2015","unstructured":"Dilwali, S., Kao, S. Y., Fujita, T., Landegger, L. D. & Stankovic, K. M. Nonsteroidal anti-inflammatory medications are cytostatic against human vestibular schwannomas. Transl. Res. 166, 1\u201311 (2015).","journal-title":"Transl. Res."},{"key":"60156_CR6","doi-asserted-by":"publisher","first-page":"170","DOI":"10.4161\/15384047.2014.972765","volume":"16","author":"S Dilwali","year":"2015","unstructured":"Dilwali, S., Roberts, D. & Stankovic, K. M. Interplay between VEGF-A and cMET signaling in human vestibular schwannomas and schwann cells. Cancer Biol. Ther. 16, 170\u2013175 (2015).","journal-title":"Cancer Biol. Ther."},{"key":"60156_CR7","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1038\/s41598-018-23609-7","volume":"8","author":"JE Sagers","year":"2018","unstructured":"Sagers, J. E. et al. Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma. Sci. Reports. 8, 5437 (2018).","journal-title":"Sci. Reports."},{"key":"60156_CR8","doi-asserted-by":"publisher","first-page":"e0197350","DOI":"10.1371\/journal.pone.0197350","volume":"13","author":"The Synodos for, N. F. C.","year":"2018","unstructured":"The Synodos for, N. F. C. et al. Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLOS ONE. 13, e0197350 (2018).","journal-title":"PLOS ONE."},{"key":"60156_CR9","first-page":"400","volume":"1826","author":"KA Morrow","year":"2012","unstructured":"Morrow, K. A. & Shevde, L. A. Merlin: the wizard requires protein stability to function as a tumor suppressor. Biochim. Biophys. Acta. 1826, 400\u2013406 (2012).","journal-title":"Biochim. Biophys. Acta."},{"key":"60156_CR10","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1016\/j.wneu.2018.06.010","volume":"117","author":"F Zhao","year":"2018","unstructured":"Zhao, F. et al. Deregulation of the Hippo Pathway Promotes Tumor Cell Proliferation Through YAP Activity in Human Sporadic Vestibular Schwannoma. World Neurosurg. 117, e269\u2013e279 (2018).","journal-title":"World Neurosurg."},{"key":"60156_CR11","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1158\/0008-5472.CAN-06-1608","volume":"67","author":"H Morrison","year":"2007","unstructured":"Morrison, H. et al. Merlin\/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res. 67, 520\u2013527 (2007).","journal-title":"Cancer Res."},{"key":"60156_CR12","doi-asserted-by":"publisher","first-page":"E2077","DOI":"10.1073\/pnas.1719966115","volume":"115","author":"Y Zhao","year":"2018","unstructured":"Zhao, Y. et al. Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. Proc. Natl Acad. Sci. USA 115, E2077\u2013e2084 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"60156_CR13","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1083\/jcb.200703010","volume":"177","author":"M Curto","year":"2007","unstructured":"Curto, M., Cole, B. K., Lallemand, D., Liu, C. H. & McClatchey, A. I. Contact-dependent inhibition of EGFR signaling by Nf2\/Merlin. J. Cell Biol. 177, 893\u2013903 (2007).","journal-title":"J. Cell Biol."},{"key":"60156_CR14","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1101\/gad.189601","volume":"15","author":"H Morrison","year":"2001","unstructured":"Morrison, H. et al. The NF2 tumor suppressor gene product, merlin, mediates contact inhibition of growth through interactions with CD44. Genes. Dev. 15, 968\u2013980 (2001).","journal-title":"Genes. Dev."},{"key":"60156_CR15","doi-asserted-by":"publisher","first-page":"16981","DOI":"10.18632\/oncotarget.4858","volume":"6","author":"RL Beauchamp","year":"2015","unstructured":"Beauchamp, R. L. et al. A high-throughput kinome screen reveals serum\/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. Oncotarget. 6, 16981\u201316997 (2015).","journal-title":"Oncotarget."},{"key":"60156_CR16","doi-asserted-by":"publisher","first-page":"4250","DOI":"10.1128\/MCB.01581-08","volume":"29","author":"MF James","year":"2009","unstructured":"James, M. F. et al. NF2\/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol. Cell Biol. 29, 4250\u20134261 (2009).","journal-title":"Mol. Cell Biol."},{"key":"60156_CR17","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1158\/1541-7786.MCR-11-0425-T","volume":"10","author":"MF James","year":"2012","unstructured":"James, M. F. et al. Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types. Mol. Cancer Res. 10, 649\u2013659 (2012).","journal-title":"Mol. Cancer Res."},{"key":"60156_CR18","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.tcb.2009.02.006","volume":"19","author":"AI McClatchey","year":"2009","unstructured":"McClatchey, A. I. & Fehon, R. G. Merlin and the ERM proteins\u2013regulators of receptor distribution and signaling at the cell cortex. Trends Cell Biol. 19, 198\u2013206 (2009).","journal-title":"Trends Cell Biol."},{"key":"60156_CR19","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1093\/neuonc\/nos146","volume":"14","author":"MA Karajannis","year":"2012","unstructured":"Karajannis, M. A. et al. Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas. Neuro Oncol. 14, 1163\u20131170 (2012).","journal-title":"Neuro Oncol."},{"key":"60156_CR20","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s11060-014-1710-0","volume":"122","author":"S Goutagny","year":"2015","unstructured":"Goutagny, S. et al. Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas. J. Neurooncol. 122, 313\u2013320 (2015).","journal-title":"J. Neurooncol."},{"key":"60156_CR21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante, M. & Sabatini, D. M. mTOR signaling in growth control and disease. Cell. 149, 274\u2013293 (2012).","journal-title":"Cell."},{"key":"60156_CR22","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1093\/neuonc\/noy046","volume":"20","author":"SP Angus","year":"2018","unstructured":"Angus, S. P. et al. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro Oncol. 20, 1185\u20131196 (2018).","journal-title":"Neuro Oncol."},{"key":"60156_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/nrd4175","volume":"13","author":"AW Boyd","year":"2014","unstructured":"Boyd, A. W., Bartlett, P. F. & Lackmann, M. Therapeutic targeting of EPH receptors and their ligands. Nat. Rev. Drug. Discov. 13, 39\u201362 (2014).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"60156_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.heares.2014.05.006","volume":"315","author":"S Dilwali","year":"2014","unstructured":"Dilwali, S. et al. Primary culture of human Schwann and schwannoma cells: improved and simplified protocol. Hear. Res. 315, 25\u201333 (2014).","journal-title":"Hear. Res."},{"key":"60156_CR25","doi-asserted-by":"crossref","unstructured":"Landegger, L. D. et al. A Unified Methodological Framework for Vestibular Schwannoma Research. J Vis Exp (2017).","DOI":"10.3791\/55827"},{"key":"60156_CR26","doi-asserted-by":"publisher","first-page":"8815","DOI":"10.1038\/sj.onc.1208110","volume":"23","author":"T Wiederhold","year":"2004","unstructured":"Wiederhold, T. et al. Magicin, a novel cytoskeletal protein associates with the NF2 tumor suppressor merlin and Grb2. Oncogene. 23, 8815\u20138825 (2004).","journal-title":"Oncogene."},{"key":"60156_CR27","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods. 9, 676\u2013682 (2012).","journal-title":"Nat. Methods."},{"key":"60156_CR28","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/labinvest.2016.88","volume":"96","author":"H Li","year":"2016","unstructured":"Li, H., Chang, L. J., Neubauer, D. R., Muir, D. F. & Wallace, M. R. Immortalization of human normal and NF1 neurofibroma Schwann cells. Lab. Invest. 96, 1105\u20131115 (2016).","journal-title":"Lab. Invest."},{"key":"60156_CR29","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1126\/science.1247005","volume":"343","author":"O Shalem","year":"2014","unstructured":"Shalem, O. et al. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science. 343, 84\u201387 (2014).","journal-title":"Science."},{"key":"60156_CR30","unstructured":"Chou, T. C. & Martin, N. CompuSyn for drug combinations. pc software and user\u2019s guide. ComboSyn Inc Paramus NJ (2005)."},{"key":"60156_CR31","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou, T. C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70, 440\u2013446 (2010).","journal-title":"Cancer Res."},{"key":"60156_CR32","doi-asserted-by":"publisher","first-page":"14676","DOI":"10.1073\/pnas.1512570112","volume":"112","author":"X Gao","year":"2015","unstructured":"Gao, X. et al. Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model. Proc. Natl Acad. Sci. USA 112, 14676\u201314681 (2015).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"60156_CR33","first-page":"1601","volume":"13","author":"ID Bassukas","year":"1993","unstructured":"Bassukas, I. D. A generalized \u201ctumor growth delay\u201d assay for quantifying alterations of tumor regrowth patterns. Anticancer. Res. 13, 1601\u20131606 (1993).","journal-title":"Anticancer. Res."},{"key":"60156_CR34","doi-asserted-by":"publisher","first-page":"164","DOI":"10.3109\/09553000903419304","volume":"86","author":"E Demidenko","year":"2010","unstructured":"Demidenko, E. Three endpoints of in vivo tumour radiobiology and their statistical estimation. Int. J. Radiat. Biol. 86, 164\u2013173 (2010).","journal-title":"Int. J. Radiat. Biol."},{"key":"60156_CR35","first-page":"553","volume":"6","author":"F Winkler","year":"2004","unstructured":"Winkler, F. et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell. 6, 553\u2013563 (2004).","journal-title":"Cancer Cell."},{"key":"60156_CR36","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","volume":"33","author":"A Ianevski","year":"2017","unstructured":"Ianevski, A., He, L., Aittokallio, T. & Tang, J. SynergyFinder: a web application for analyzing drug combination dose-response matrix data. Bioinformatics. 33, 2413\u20132415 (2017).","journal-title":"Bioinformatics."},{"key":"60156_CR37","doi-asserted-by":"publisher","first-page":"e1006752","DOI":"10.1371\/journal.pcbi.1006752","volume":"15","author":"A Malyutina","year":"2019","unstructured":"Malyutina, A. et al. Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer. PLoS Comput. Biol. 15, e1006752 (2019).","journal-title":"PLoS Comput. Biol."},{"key":"60156_CR38","doi-asserted-by":"publisher","first-page":"31666","DOI":"10.18632\/oncotarget.15912","volume":"8","author":"AM Petrilli","year":"2017","unstructured":"Petrilli, A. M. et al. Ponatinib promotes a G1 cell-cycle arrest of merlin\/NF2-deficient human schwann cells. Oncotarget. 8, 31666\u201331681 (2017).","journal-title":"Oncotarget."},{"key":"60156_CR39","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1158\/1535-7163.MCT-17-0417","volume":"16","author":"MA Fuse","year":"2017","unstructured":"Fuse, M. A. et al. Combination Therapy with c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. Mol. Cancer Ther. 16, 2387\u20132398 (2017).","journal-title":"Mol. Cancer Ther."},{"key":"60156_CR40","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.ctrv.2010.02.015","volume":"36","author":"J Araujo","year":"2010","unstructured":"Araujo, J. & Logothetis, C. Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat. Rev. 36, 492\u2013500 (2010).","journal-title":"Cancer Treat. Rev."},{"key":"60156_CR41","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3389\/fcell.2019.00070","volume":"7","author":"MG Sugiyama","year":"2019","unstructured":"Sugiyama, M. G., Fairn, G. D. & Antonescu, C. N. Akt-ing Up Just About Everywhere: Compartment-Specific Akt Activation and Function in Receptor Tyrosine Kinase Signaling. Front. Cell Dev. Biol. 7, 70 (2019).","journal-title":"Front. Cell Dev. Biol."},{"key":"60156_CR42","doi-asserted-by":"publisher","first-page":"4762","DOI":"10.1158\/0008-5472.CAN-13-3627","volume":"74","author":"JL Yori","year":"2014","unstructured":"Yori, J. L. et al. Combined SFK\/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression. Cancer Res. 74, 4762\u20134771 (2014).","journal-title":"Cancer Res."},{"key":"60156_CR43","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1158\/0008-5472.CAN-09-3107","volume":"70","author":"HK Wong","year":"2010","unstructured":"Wong, H. K. et al. Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res. 70, 3483\u20133493 (2010).","journal-title":"Cancer Res."},{"key":"60156_CR44","first-page":"409","volume":"14","author":"G Hung","year":"1999","unstructured":"Hung, G. et al. Establishment of primary vestibular schwannoma cultures from neurofibromatosis type-2 patients. Int. J. Oncol. 14, 409\u2013415 (1999).","journal-title":"Int. J. Oncol."},{"key":"60156_CR45","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1101\/gad.14.13.1617","volume":"14","author":"M Giovannini","year":"2000","unstructured":"Giovannini, M. et al. Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes. Dev. 14, 1617\u20131630 (2000).","journal-title":"Genes. Dev."},{"key":"60156_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/hmg\/ddu414","volume":"24","author":"JR Gehlhausen","year":"2015","unstructured":"Gehlhausen, J. R. et al. A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation. Hum. Mol. Genet. 24, 1\u20138 (2015).","journal-title":"Hum. Mol. Genet."},{"key":"60156_CR47","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1101\/gad.13.8.978","volume":"13","author":"M Giovannini","year":"1999","unstructured":"Giovannini, M. et al. Schwann cell hyperplasia and tumors in transgenic mice expressing a naturally occurring mutant NF2 protein. Genes. Dev. 13, 978\u2013986 (1999).","journal-title":"Genes. Dev."},{"key":"60156_CR48","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1101\/gad.226302","volume":"16","author":"M Kalamarides","year":"2002","unstructured":"Kalamarides, M. et al. Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse. Genes. Dev. 16, 1060\u20131065 (2002).","journal-title":"Genes. Dev."},{"key":"60156_CR49","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1101\/gad.11.10.1253","volume":"11","author":"AI McClatchey","year":"1997","unstructured":"McClatchey, A. I., Saotome, I., Ramesh, V., Gusella, J. F. & Jacks, T. The Nf2 tumor suppressor gene product is essential for extraembryonic development immediately prior to gastrulation. Genes. Dev. 11, 1253\u20131265 (1997).","journal-title":"Genes. Dev."},{"key":"60156_CR50","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/0896-6273(92)90279-M","volume":"8","author":"A Messing","year":"1992","unstructured":"Messing, A. et al. P0 promoter directs expression of reporter and toxin genes to Schwann cells of transgenic mice. Neuron. 8, 507\u2013520 (1992).","journal-title":"Neuron."},{"key":"60156_CR51","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo, L. J. et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47, 6658\u20136661 (2004).","journal-title":"J. Med. Chem."},{"key":"60156_CR52","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11060-016-2150-9","volume":"129","author":"NX Bonne","year":"2016","unstructured":"Bonne, N. X. et al. An allograft mouse model for the study of hearing loss secondary to vestibular schwannoma growth. J. Neurooncol. 129, 47\u201356 (2016).","journal-title":"J. Neurooncol."},{"key":"60156_CR53","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1097\/MAO.0000000000001766","volume":"39","author":"CT Dinh","year":"2018","unstructured":"Dinh, C. T. et al. A Xenograft Model of Vestibular Schwannoma and Hearing Loss. Otol. Neurotol. 39, e362\u2013e369 (2018).","journal-title":"Otol. Neurotol."},{"key":"60156_CR54","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41596-018-0105-7","volume":"14","author":"J Chen","year":"2019","unstructured":"Chen, J. et al. A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma. Nat. Protoc. 14, 541\u2013555 (2019).","journal-title":"Nat. Protoc."},{"key":"60156_CR55","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11060-016-2276-9","volume":"131","author":"KA Morris","year":"2017","unstructured":"Morris, K. A. et al. Toxicity profile of bevacizumab in the UK Neurofibromatosis type 2 cohort. J. Neurooncol. 131, 117\u2013124 (2017).","journal-title":"J. Neurooncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60156-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60156-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60156-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T07:49:16Z","timestamp":1670312956000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-60156-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,6]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["60156"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-60156-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,6]]},"assertion":[{"value":"4 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4211"}}